Millipore Sigma Vibrant Logo

05-23-3831 BQ-123, Sodium Salt - CAS - Calbiochem

A highly potent, selective, and competitive ETA (endothelin) receptor antagonist (Ki = 40 nM for ETA versus Ki = 2.5 µM for ETB).

BQ-123, Sodium Salt - CAS - Calbiochem: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。
Primary Target: ETA (endothelin) receptor antagonist
View This Product on Sigma-Aldrich
05-23-3831
  
価格を検索中…
価格が見つかりません
Minimum Quantity needs to be mulitiple of
Maximum Quantity is
弊社照会 詳細を表示　
値引
()
 
—
弊社照会
—
現在国内在庫なし 現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

       

      お問合せください

      概要

      Replacement Information

      主要スペック表

      Empirical Formula
      C₃₁H₄₁N₆O₇ · Na
      Description
      OverviewA highly potent, selective, and competitive ETA (endothelin) receptor antagonist (Ki = 40 nM for ETA versus Ki = 2.5 μM for ETB).
      Catalogue Number05-23-3831
      Brand Family Calbiochem®
      References
      ReferencesNambi, P., et al. 1996. J. Pharmacol. Exp. Ther. 277, 1567.
      Bax, W.A., and Saxena, P.R. 1994. Trends Pharmacol. Sci. 15, 379.
      Ihara, M., et al. 1991. Biochem. Biophys. Res. Commun. 178, 132.
      Product Information
      ATP CompetitiveN
      FormWhite solid
      FormulationSupplied as a sodium salt. Sold on the basis of peptide content.
      Hill FormulaC₃₁H₄₁N₆O₇ · Na
      Chemical formulaC₃₁H₄₁N₆O₇ · Na
      Hygroscopic Hygroscopic
      ReversibleN
      Sold on the basis of peptide contentY
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetETA (endothelin) receptor antagonist
      Primary Target K<sub>i</sub>40 nM for ETA versus 2.5 µM for ETB
      Purity≥95% by HPLC
      Physicochemical Information
      Cell permeableN
      Peptide ContentY
      Peptide SequenceCyclo(D-Asp-Pro-D-Val-Leu-D-Trp, Na)
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      05-23-3831 0

      Documentation

      BQ-123, Sodium Salt - CAS - Calbiochem (M)SDS

      タイトル

      英語版製品安全データシート（(M)SDS） 

      BQ-123, Sodium Salt - CAS - Calbiochem 試験成績書（CoA）

      タイトルロット番号
      05-23-3831

      参考資料

      参考資料の概要
      Nambi, P., et al. 1996. J. Pharmacol. Exp. Ther. 277, 1567.
      Bax, W.A., and Saxena, P.R. 1994. Trends Pharmacol. Sci. 15, 379.
      Ihara, M., et al. 1991. Biochem. Biophys. Res. Commun. 178, 132.
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision31-May-2011 JSW
      DescriptionA highly potent and selective ETA (endothelin) receptor antagonist (Ki = 40 nM for ETA versus 2.5 µM for ETB).
      FormWhite solid
      FormulationSupplied as a sodium salt. Sold on the basis of peptide content.
      Chemical formulaC₃₁H₄₁N₆O₇ · Na
      Peptide SequenceCyclo(D-Asp-Pro-D-Val-Leu-D-Trp, Na)
      Purity≥95% by HPLC
      SolubilityH₂O (1 mg/ml)
      Storage -20°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesNambi, P., et al. 1996. J. Pharmacol. Exp. Ther. 277, 1567.
      Bax, W.A., and Saxena, P.R. 1994. Trends Pharmacol. Sci. 15, 379.
      Ihara, M., et al. 1991. Biochem. Biophys. Res. Commun. 178, 132.